GET DAILY SIGNALSWhy Is 10x Genomics (TXG) Stock Down -6.70% Today?
Key Takeaways
- Shares of TXG fell roughly 6.70% in Thursday's session, extending a sharp post-earnings pullback.
- The primary driver was continued repricing following the company's third-quarter report, which showed a steep decline in instrument revenue as customers delayed purchases ahead of the new Atera platform.
- A fresh wave of analyst price-target cuts — from J.P. Morgan, Barclays, UBS and Stephens — reinforced the bearish tone.
- Technical deterioration and stretched valuation after a more than 350% rally weighed on sentiment, alongside broader life sciences tools weakness.
- Traders are now watching whether shares hold key support levels and how quickly Atera shipments ramp through year-end.
- For additional detail on Price Targets, Earnings, and Forecast, explore the dedicated pages for this ticker.
- You can also track real-time momentum across the market by exploring Trending AI Robots.
Opening Summary
10x Genomics, Inc. (TXG), the Pleasanton, California-based life science technology company known for its single-cell and spatial biology instruments, consumables and software, tumbled in Thursday's trading session. The stock was last quoted around $57.89, down $4.16, or roughly 6.70%, from the prior session's close of $62.05. The decline extended a volatile stretch that began after the company's November 5 earnings report, as investors continued to digest slowing instrument sales, a series of Wall Street target cuts, and a technical breakdown from recent highs.
Post-Earnings Repricing and the Atera Transition
The move remains closely tied to the market's ongoing reaction to TXG's third-quarter results. The company beat Wall Street estimates on both revenue and the bottom line, posting revenue of roughly $150.7 million and a narrower-than-expected GAAP loss of $0.15 per share, while also raising its full-year 2026 revenue outlook. Yet the headline beat masked a sharp decline in instrument revenue, which fell roughly 43% as customers held off purchasing existing systems in anticipation of Atera, the company's next-generation spatial biology platform whose commercial shipments only began in late September.
Management framed the shortfall as a demand-timing issue rather than a loss of demand, pointing to strong order flow, robust consumables growth and improving gross margins. But the market has continued to focus on the near-term top-line softness and the transition risk, keeping the stock under pressure days after the report.
Analyst Target Cuts
Compounding the selling pressure, several analysts have trimmed their price targets on TXG following the quarterly update. J.P. Morgan lowered its target to $65 from $70 while maintaining a Neutral rating; Barclays reduced its target to $70 while staying Overweight; UBS cut its target to $61, citing valuation concerns; and Stephens reiterated a Hold with a $65 target. The recurring theme across the notes was uncertainty over how much of the Atera momentum represents incremental demand versus a near-term replacement of existing products, and whether a rich valuation can be sustained through the transition.
Technical Breakdown and Valuation Pressure
The slide also reflects a technical and sentiment-driven unwind. After a meteoric rise of more than 350% over the past year, TXG has now pulled back sharply from its autumn high, breaking below its 50-day moving average and displaying weakening short-term momentum. With the stock trading well above its 200-day average and carrying an elevated valuation multiple relative to its still-negative earnings, the correction has left the shares vulnerable to further de-risking as momentum-oriented investors lock in gains.
Market Context and Trading Activity
The decline unfolded against a backdrop of choppy trading across the life sciences tools and genomics complex, where several peers have also experienced elevated volatility around earnings and product-transition headlines. TXG has been notably volatile, posting numerous large daily swings over the past year. The stock's retreat from its highs has been characterized by heavy trading and sharp intraday moves, suggesting active institutional repositioning rather than a single isolated catalyst. Technical support near the mid-$50s has become a key level for traders to monitor.
What Comes Next for TXG
Looking ahead, investors will focus on the pace of Atera production, installations and customer onboarding, with management targeting roughly 50 placements per quarter and reiterating that production capacity — not demand — is the primary constraint. The company's next quarterly report will offer a clearer read on whether the instrument-revenue dip was transitory and whether consumables momentum can accelerate as more Atera systems come online. Key risks include continued valuation compression, execution on the Atera ramp, competitive dynamics in spatial biology, and the broader sentiment toward high-multiple life sciences names. Until the growth picture reaccelerates, TXG shares may remain volatile.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics and the symbols they trade, giving traders a way to monitor which automated approaches are leading the market right now. Explore the Trending AI Robots page to see today's top-performing strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TXG's Indicator enters downward trend
The Aroon Indicator for TXG entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 229 similar instances where the Aroon Indicator formed such a pattern. In 204 of the 229 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 67 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 210 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.356) is normal, around the industry mean (4.142). P/E Ratio (-100.475) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement